 Nichole Carlson
Concepts (499)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bayes Theorem | 6 | 2020 | 305 | 1.490 |
Why?
| | Luteinizing Hormone | 11 | 2020 | 187 | 1.260 |
Why?
| | Models, Statistical | 6 | 2020 | 656 | 1.130 |
Why?
| | Hydrocortisone | 6 | 2015 | 332 | 1.020 |
Why?
| | Hormones | 3 | 2017 | 137 | 0.970 |
Why?
| | Hypothalamo-Hypophyseal System | 7 | 2017 | 270 | 0.800 |
Why?
| | Data Interpretation, Statistical | 3 | 2017 | 337 | 0.770 |
Why?
| | Diabetes Complications | 1 | 2022 | 226 | 0.760 |
Why?
| | Metadata | 1 | 2018 | 5 | 0.720 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2019 | 59 | 0.720 |
Why?
| | Radiography, Thoracic | 1 | 2019 | 179 | 0.690 |
Why?
| | State Health Plans | 2 | 2008 | 32 | 0.670 |
Why?
| | Computer Simulation | 4 | 2017 | 923 | 0.660 |
Why?
| | Ovary | 3 | 2017 | 210 | 0.630 |
Why?
| | Models, Biological | 3 | 2017 | 1763 | 0.610 |
Why?
| | Residence Characteristics | 6 | 2010 | 290 | 0.600 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2015 | 161 | 0.590 |
Why?
| | Genome | 1 | 2018 | 262 | 0.590 |
Why?
| | Reproduction | 1 | 2017 | 200 | 0.590 |
Why?
| | Child Health Services | 2 | 2008 | 183 | 0.560 |
Why?
| | Software | 2 | 2019 | 532 | 0.560 |
Why?
| | Computational Biology | 1 | 2018 | 481 | 0.550 |
Why?
| | Contraceptives, Oral, Combined | 7 | 2011 | 15 | 0.550 |
Why?
| | Tomography, X-Ray Computed | 3 | 2019 | 2462 | 0.540 |
Why?
| | Brain Injuries | 5 | 2010 | 471 | 0.520 |
Why?
| | Health Services for the Aged | 2 | 2019 | 79 | 0.520 |
Why?
| | Biometry | 2 | 2017 | 85 | 0.510 |
Why?
| | Health Services Accessibility | 4 | 2010 | 798 | 0.490 |
Why?
| | Antiparkinson Agents | 3 | 2009 | 29 | 0.490 |
Why?
| | Environment Design | 3 | 2010 | 19 | 0.490 |
Why?
| | Pulsatile Flow | 1 | 2013 | 57 | 0.490 |
Why?
| | Obesity | 11 | 2022 | 2711 | 0.480 |
Why?
| | Circadian Rhythm | 4 | 2013 | 458 | 0.480 |
Why?
| | Dehydroepiandrosterone | 1 | 2013 | 53 | 0.470 |
Why?
| | Outpatients | 4 | 2022 | 287 | 0.450 |
Why?
| | Specimen Handling | 1 | 2013 | 169 | 0.430 |
Why?
| | Humans | 82 | 2023 | 117633 | 0.430 |
Why?
| | Follicle Stimulating Hormone | 8 | 2020 | 220 | 0.430 |
Why?
| | Saliva | 1 | 2013 | 219 | 0.430 |
Why?
| | Walking | 4 | 2010 | 434 | 0.410 |
Why?
| | Parkinson Disease | 4 | 2009 | 353 | 0.410 |
Why?
| | Female | 65 | 2022 | 63247 | 0.400 |
Why?
| | Levodopa | 2 | 2007 | 25 | 0.390 |
Why?
| | Hypogonadism | 2 | 2015 | 74 | 0.390 |
Why?
| | Oregon | 8 | 2011 | 71 | 0.390 |
Why?
| | Activities of Daily Living | 3 | 2010 | 386 | 0.380 |
Why?
| | Adult | 45 | 2023 | 32118 | 0.380 |
Why?
| | Endocrine System | 1 | 2009 | 23 | 0.370 |
Why?
| | Testosterone | 2 | 2010 | 333 | 0.370 |
Why?
| | Aged | 23 | 2022 | 20249 | 0.350 |
Why?
| | Technology | 1 | 2009 | 79 | 0.340 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2031 | 0.340 |
Why?
| | Prenatal Care | 1 | 2010 | 260 | 0.340 |
Why?
| | Cerebral Ventricles | 1 | 2007 | 53 | 0.330 |
Why?
| | Levonorgestrel | 4 | 2011 | 30 | 0.330 |
Why?
| | Metrorrhagia | 3 | 2011 | 4 | 0.330 |
Why?
| | Health Behavior | 3 | 2010 | 711 | 0.320 |
Why?
| | Perception | 2 | 2007 | 313 | 0.310 |
Why?
| | Methylphenidate | 1 | 2007 | 35 | 0.310 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2007 | 61 | 0.310 |
Why?
| | Cognition Disorders | 3 | 2008 | 580 | 0.300 |
Why?
| | Young Adult | 14 | 2022 | 11077 | 0.300 |
Why?
| | Smoking Cessation | 1 | 2010 | 405 | 0.300 |
Why?
| | Estradiol | 5 | 2015 | 465 | 0.300 |
Why?
| | Male | 39 | 2022 | 60403 | 0.290 |
Why?
| | Aged, 80 and over | 11 | 2021 | 6795 | 0.290 |
Why?
| | Middle Aged | 32 | 2021 | 28659 | 0.290 |
Why?
| | Antibodies, Viral | 4 | 2023 | 535 | 0.290 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2022 | 3258 | 0.280 |
Why?
| | Longitudinal Studies | 10 | 2020 | 2668 | 0.280 |
Why?
| | Poverty | 2 | 2010 | 450 | 0.280 |
Why?
| | Healthcare Disparities | 1 | 2010 | 490 | 0.270 |
Why?
| | Time Factors | 13 | 2017 | 6906 | 0.270 |
Why?
| | Alzheimer Disease | 3 | 2021 | 462 | 0.260 |
Why?
| | Medicaid | 1 | 2008 | 404 | 0.250 |
Why?
| | Body Mass Index | 6 | 2019 | 2076 | 0.240 |
Why?
| | Socioeconomic Factors | 5 | 2010 | 1163 | 0.230 |
Why?
| | Oocytes | 2 | 2020 | 217 | 0.230 |
Why?
| | Cross-Sectional Studies | 12 | 2018 | 4630 | 0.220 |
Why?
| | Markov Chains | 3 | 2017 | 128 | 0.220 |
Why?
| | Monte Carlo Method | 3 | 2017 | 156 | 0.220 |
Why?
| | Aging | 4 | 2008 | 1690 | 0.220 |
Why?
| | Gliosis | 1 | 2021 | 28 | 0.210 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 81 | 0.210 |
Why?
| | Healthy Aging | 1 | 2021 | 19 | 0.210 |
Why?
| | Disability Evaluation | 4 | 2018 | 310 | 0.210 |
Why?
| | Doxycycline | 2 | 2011 | 56 | 0.210 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2021 | 87 | 0.210 |
Why?
| | Ethinyl Estradiol | 2 | 2011 | 14 | 0.200 |
Why?
| | Preimplantation Diagnosis | 1 | 2020 | 3 | 0.200 |
Why?
| | Oocyte Donation | 1 | 2020 | 5 | 0.200 |
Why?
| | Memory, Episodic | 1 | 2021 | 39 | 0.200 |
Why?
| | Weight Gain | 2 | 2022 | 513 | 0.200 |
Why?
| | Sarcoidosis | 1 | 2022 | 123 | 0.200 |
Why?
| | Prescription Drugs | 1 | 2022 | 114 | 0.200 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 172 | 0.200 |
Why?
| | Prospective Studies | 8 | 2022 | 6422 | 0.200 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2020 | 34 | 0.200 |
Why?
| | Apomorphine | 3 | 2009 | 9 | 0.190 |
Why?
| | Menstruation | 2 | 1991 | 34 | 0.190 |
Why?
| | Fractals | 1 | 2019 | 8 | 0.190 |
Why?
| | Aromatase Inhibitors | 1 | 2020 | 51 | 0.190 |
Why?
| | Comprehensive Health Care | 1 | 2019 | 22 | 0.190 |
Why?
| | Hospitalization | 5 | 2022 | 1774 | 0.190 |
Why?
| | Radial Nerve | 1 | 1999 | 12 | 0.190 |
Why?
| | Nerve Compression Syndromes | 1 | 1999 | 29 | 0.190 |
Why?
| | Quality of Life | 5 | 2018 | 2354 | 0.190 |
Why?
| | Human Growth Hormone | 2 | 2014 | 36 | 0.190 |
Why?
| | Astrocytes | 1 | 2021 | 164 | 0.180 |
Why?
| | Gonadotropins | 2 | 2015 | 33 | 0.180 |
Why?
| | White Matter | 1 | 2021 | 110 | 0.180 |
Why?
| | Vital Capacity | 1 | 2019 | 277 | 0.180 |
Why?
| | Internet | 2 | 2018 | 656 | 0.180 |
Why?
| | Spirometry | 1 | 2019 | 313 | 0.180 |
Why?
| | Health Status | 3 | 2010 | 791 | 0.180 |
Why?
| | Hip Fractures | 1 | 2019 | 81 | 0.170 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 1199 | 0.170 |
Why?
| | Datasets as Topic | 1 | 2018 | 98 | 0.170 |
Why?
| | Contraception | 2 | 1991 | 129 | 0.170 |
Why?
| | Sheep, Domestic | 1 | 2017 | 33 | 0.170 |
Why?
| | Bibliometrics | 1 | 2018 | 63 | 0.170 |
Why?
| | Eligibility Determination | 2 | 2008 | 53 | 0.170 |
Why?
| | Rhinitis | 2 | 2010 | 123 | 0.160 |
Why?
| | Reproductive Physiological Phenomena | 1 | 2017 | 2 | 0.160 |
Why?
| | Risk Factors | 9 | 2022 | 9124 | 0.160 |
Why?
| | Respiratory Function Tests | 1 | 2019 | 596 | 0.160 |
Why?
| | Regression Analysis | 2 | 2019 | 1072 | 0.160 |
Why?
| | Premature Birth | 1 | 2020 | 258 | 0.160 |
Why?
| | Algorithms | 3 | 2017 | 1550 | 0.160 |
Why?
| | Medically Uninsured | 2 | 2008 | 134 | 0.160 |
Why?
| | Family Planning Services | 2 | 2008 | 74 | 0.160 |
Why?
| | Double-Blind Method | 7 | 2011 | 1695 | 0.150 |
Why?
| | Sinusitis | 2 | 2010 | 170 | 0.150 |
Why?
| | Metabolic Diseases | 1 | 2018 | 113 | 0.150 |
Why?
| | Hypothyroidism | 2 | 2007 | 70 | 0.150 |
Why?
| | Proton Pump Inhibitors | 1 | 2017 | 103 | 0.150 |
Why?
| | Affect | 3 | 2008 | 264 | 0.150 |
Why?
| | Low Back Pain | 1 | 2018 | 91 | 0.150 |
Why?
| | Lung | 2 | 2019 | 3645 | 0.150 |
Why?
| | Endoscopy | 2 | 2010 | 255 | 0.150 |
Why?
| | Psychomotor Performance | 3 | 2009 | 339 | 0.150 |
Why?
| | Cohort Studies | 5 | 2010 | 5112 | 0.150 |
Why?
| | Lactation | 1 | 2018 | 221 | 0.150 |
Why?
| | Adolescent | 13 | 2020 | 18902 | 0.150 |
Why?
| | Immunologic Memory | 1 | 2018 | 305 | 0.150 |
Why?
| | Reproducibility of Results | 2 | 2017 | 2948 | 0.150 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2018 | 170 | 0.150 |
Why?
| | Antibodies | 1 | 2018 | 405 | 0.150 |
Why?
| | Models, Animal | 1 | 2017 | 380 | 0.140 |
Why?
| | Personnel Selection | 1 | 2016 | 72 | 0.140 |
Why?
| | Cross-Over Studies | 5 | 2009 | 499 | 0.140 |
Why?
| | Dietary Fats | 1 | 2018 | 353 | 0.140 |
Why?
| | Recovery of Function | 2 | 2010 | 607 | 0.140 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 173 | 0.140 |
Why?
| | Otolaryngology | 1 | 2016 | 83 | 0.140 |
Why?
| | Dementia | 2 | 2008 | 196 | 0.140 |
Why?
| | Patient Dropouts | 1 | 2015 | 75 | 0.140 |
Why?
| | Decision Support Systems, Clinical | 1 | 2017 | 162 | 0.130 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2015 | 109 | 0.130 |
Why?
| | Menstrual Cycle | 3 | 2011 | 113 | 0.130 |
Why?
| | Breast Feeding | 1 | 2018 | 377 | 0.130 |
Why?
| | Retrospective Studies | 9 | 2023 | 12331 | 0.130 |
Why?
| | Acromegaly | 1 | 2014 | 14 | 0.130 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 1 | 2014 | 11 | 0.130 |
Why?
| | Pregnancy | 7 | 2020 | 5554 | 0.130 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2015 | 130 | 0.130 |
Why?
| | Biomarkers | 4 | 2021 | 3574 | 0.130 |
Why?
| | Gonadotropin-Releasing Hormone | 4 | 2020 | 206 | 0.130 |
Why?
| | Pituitary-Adrenal System | 3 | 2013 | 195 | 0.130 |
Why?
| | Brain Ischemia | 1 | 2017 | 285 | 0.130 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 936 | 0.120 |
Why?
| | Antibody Formation | 2 | 2022 | 287 | 0.120 |
Why?
| | Drug Administration Schedule | 4 | 2010 | 780 | 0.120 |
Why?
| | Interviews as Topic | 3 | 2010 | 614 | 0.120 |
Why?
| | Secretory Rate | 1 | 2013 | 17 | 0.120 |
Why?
| | Analysis of Variance | 5 | 2009 | 1451 | 0.120 |
Why?
| | Health Care Costs | 1 | 2017 | 410 | 0.120 |
Why?
| | Neurosurgical Procedures | 1 | 2014 | 148 | 0.120 |
Why?
| | Electronics | 1 | 2013 | 69 | 0.120 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 210 | 0.120 |
Why?
| | Adenoma | 1 | 2014 | 184 | 0.110 |
Why?
| | Arrhythmias, Cardiac | 1 | 2015 | 328 | 0.110 |
Why?
| | Medical Records | 1 | 2013 | 175 | 0.110 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 419 | 0.110 |
Why?
| | Urban Health | 2 | 2009 | 86 | 0.110 |
Why?
| | Wakefulness | 1 | 2013 | 160 | 0.110 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 503 | 0.110 |
Why?
| | Severity of Illness Index | 5 | 2022 | 2884 | 0.110 |
Why?
| | Age Factors | 8 | 2018 | 3223 | 0.110 |
Why?
| | Dietary Supplements | 1 | 2015 | 465 | 0.110 |
Why?
| | Insulin | 1 | 2022 | 2138 | 0.110 |
Why?
| | Memory | 3 | 2008 | 271 | 0.110 |
Why?
| | Brain | 4 | 2007 | 2699 | 0.110 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 398 | 0.110 |
Why?
| | Cognition | 3 | 2008 | 1019 | 0.110 |
Why?
| | Amenorrhea | 1 | 2011 | 30 | 0.110 |
Why?
| | Statistics as Topic | 2 | 2009 | 333 | 0.100 |
Why?
| | Progestins | 1 | 2011 | 80 | 0.100 |
Why?
| | Dopamine Agonists | 2 | 2008 | 33 | 0.100 |
Why?
| | Follow-Up Studies | 5 | 2017 | 4911 | 0.100 |
Why?
| | Contraceptives, Oral, Hormonal | 2 | 2007 | 23 | 0.100 |
Why?
| | Equipment Design | 1 | 2013 | 532 | 0.100 |
Why?
| | Birth Certificates | 1 | 2010 | 7 | 0.100 |
Why?
| | Birth Rate | 2 | 2020 | 17 | 0.100 |
Why?
| | Estrone | 1 | 2010 | 32 | 0.100 |
Why?
| | Dihydrotestosterone | 1 | 2010 | 35 | 0.100 |
Why?
| | Antibodies, Neutralizing | 2 | 2022 | 210 | 0.100 |
Why?
| | Automobile Driving | 2 | 2010 | 131 | 0.100 |
Why?
| | Live Birth | 2 | 2020 | 45 | 0.100 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2010 | 11 | 0.100 |
Why?
| | Cytokines | 2 | 2015 | 1951 | 0.100 |
Why?
| | Risk Assessment | 2 | 2017 | 3208 | 0.100 |
Why?
| | Pregnancy Rate | 2 | 2020 | 55 | 0.100 |
Why?
| | Diet | 1 | 2018 | 1115 | 0.100 |
Why?
| | Geographic Information Systems | 2 | 2010 | 38 | 0.100 |
Why?
| | Fertilization in Vitro | 2 | 2020 | 71 | 0.100 |
Why?
| | Thyroxine | 2 | 2007 | 65 | 0.100 |
Why?
| | Abortion, Induced | 2 | 2008 | 66 | 0.100 |
Why?
| | Cities | 1 | 2010 | 76 | 0.100 |
Why?
| | United States | 6 | 2020 | 12768 | 0.100 |
Why?
| | Myocardial Infarction | 1 | 2017 | 1152 | 0.090 |
Why?
| | Personality | 1 | 2011 | 119 | 0.090 |
Why?
| | Sex Factors | 5 | 2018 | 1918 | 0.090 |
Why?
| | Registries | 1 | 2017 | 1969 | 0.090 |
Why?
| | Independent Living | 1 | 2010 | 77 | 0.090 |
Why?
| | Electrical Equipment and Supplies | 1 | 2009 | 8 | 0.090 |
Why?
| | Rehabilitation Centers | 1 | 2009 | 35 | 0.090 |
Why?
| | Telecommunications | 1 | 2009 | 21 | 0.090 |
Why?
| | Treatment Outcome | 7 | 2015 | 9353 | 0.090 |
Why?
| | Mortality | 1 | 2011 | 317 | 0.090 |
Why?
| | Postmenopause | 1 | 2010 | 320 | 0.090 |
Why?
| | Rural Health | 1 | 2009 | 81 | 0.090 |
Why?
| | Progesterone | 3 | 2015 | 258 | 0.090 |
Why?
| | Drug Interactions | 2 | 2007 | 372 | 0.090 |
Why?
| | Pattern Recognition, Automated | 1 | 2009 | 99 | 0.090 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 6 | 0.090 |
Why?
| | Child, Preschool | 4 | 2018 | 9714 | 0.090 |
Why?
| | Life Change Events | 1 | 2009 | 134 | 0.080 |
Why?
| | Exercise | 3 | 2010 | 1809 | 0.080 |
Why?
| | Vaccinia | 1 | 2007 | 19 | 0.080 |
Why?
| | Smallpox Vaccine | 1 | 2007 | 23 | 0.080 |
Why?
| | Povidone-Iodine | 1 | 2007 | 13 | 0.080 |
Why?
| | Foot | 1 | 2009 | 123 | 0.080 |
Why?
| | Vaccinia virus | 1 | 2007 | 29 | 0.080 |
Why?
| | Ointments | 1 | 2007 | 27 | 0.080 |
Why?
| | Monitoring, Ambulatory | 1 | 2009 | 93 | 0.080 |
Why?
| | Logistic Models | 2 | 2010 | 2018 | 0.080 |
Why?
| | Pregnancy, Unplanned | 1 | 2008 | 40 | 0.080 |
Why?
| | CD4 Lymphocyte Count | 2 | 2020 | 280 | 0.080 |
Why?
| | Parkinsonian Disorders | 1 | 2007 | 30 | 0.080 |
Why?
| | Disease Progression | 3 | 2015 | 2541 | 0.080 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 2007 | 11 | 0.080 |
Why?
| | Atrophy | 1 | 2007 | 153 | 0.080 |
Why?
| | Wounds, Gunshot | 1 | 2009 | 150 | 0.080 |
Why?
| | Counseling | 1 | 2010 | 377 | 0.080 |
Why?
| | Time Perception | 1 | 2007 | 22 | 0.080 |
Why?
| | Awareness | 1 | 2007 | 93 | 0.080 |
Why?
| | Albumins | 1 | 2007 | 96 | 0.080 |
Why?
| | Antigens, Bacterial | 1 | 2007 | 123 | 0.080 |
Why?
| | Population Surveillance | 1 | 2010 | 449 | 0.080 |
Why?
| | Antibodies, Bacterial | 1 | 2007 | 137 | 0.080 |
Why?
| | Antigens, Viral | 1 | 2007 | 181 | 0.080 |
Why?
| | Suicide, Attempted | 1 | 2009 | 298 | 0.080 |
Why?
| | Tremor | 1 | 2007 | 45 | 0.080 |
Why?
| | Internship and Residency | 1 | 2016 | 1026 | 0.080 |
Why?
| | Blood-Brain Barrier | 1 | 2007 | 115 | 0.070 |
Why?
| | Movement | 1 | 2009 | 275 | 0.070 |
Why?
| | Infant | 3 | 2010 | 8255 | 0.070 |
Why?
| | Cost-Benefit Analysis | 1 | 2009 | 553 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2017 | 1819 | 0.070 |
Why?
| | Antibodies, Monoclonal | 2 | 2022 | 1267 | 0.070 |
Why?
| | Paroxetine | 1 | 2005 | 7 | 0.070 |
Why?
| | Treatment Failure | 2 | 2022 | 340 | 0.070 |
Why?
| | Health Policy | 1 | 2008 | 354 | 0.070 |
Why?
| | Neurologic Examination | 2 | 2008 | 125 | 0.070 |
Why?
| | Attitude to Health | 1 | 2008 | 412 | 0.070 |
Why?
| | Administration, Oral | 1 | 2007 | 786 | 0.070 |
Why?
| | Child | 5 | 2018 | 18649 | 0.060 |
Why?
| | Health Promotion | 1 | 2010 | 682 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1897 | 0.060 |
Why?
| | Family | 1 | 2008 | 567 | 0.060 |
Why?
| | Likelihood Functions | 2 | 2017 | 140 | 0.060 |
Why?
| | Patient Compliance | 1 | 2008 | 588 | 0.060 |
Why?
| | Sexual Behavior | 1 | 2008 | 490 | 0.060 |
Why?
| | Linear Models | 2 | 2020 | 871 | 0.060 |
Why?
| | Emotions | 1 | 2007 | 473 | 0.060 |
Why?
| | Physical Fitness | 1 | 2004 | 188 | 0.060 |
Why?
| | Sex Characteristics | 1 | 2007 | 681 | 0.060 |
Why?
| | Temporomandibular Joint Dysfunction Syndrome | 1 | 2002 | 4 | 0.060 |
Why?
| | Vaccines | 1 | 2007 | 361 | 0.060 |
Why?
| | Facial Pain | 1 | 2002 | 14 | 0.060 |
Why?
| | B-Lymphocytes | 1 | 2007 | 816 | 0.060 |
Why?
| | Acids | 1 | 2002 | 20 | 0.060 |
Why?
| | Motor Activity | 1 | 2007 | 723 | 0.060 |
Why?
| | Administration, Cutaneous | 2 | 2015 | 128 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1228 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2011 | 1422 | 0.060 |
Why?
| | Physical Examination | 2 | 2018 | 266 | 0.050 |
Why?
| | Animals | 5 | 2018 | 34350 | 0.050 |
Why?
| | Ovarian Follicle | 1 | 2002 | 61 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 3 | 2008 | 3214 | 0.050 |
Why?
| | Odds Ratio | 3 | 2010 | 1038 | 0.050 |
Why?
| | Patient Acceptance of Health Care | 1 | 2007 | 686 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 148 | 0.050 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2022 | 82 | 0.050 |
Why?
| | Rheumatoid Factor | 1 | 2022 | 151 | 0.050 |
Why?
| | Puberty | 1 | 2002 | 136 | 0.050 |
Why?
| | Oocyte Retrieval | 1 | 2020 | 12 | 0.050 |
Why?
| | Immunoglobulin A | 1 | 2022 | 171 | 0.050 |
Why?
| | Immunoglobulin M | 1 | 2022 | 245 | 0.050 |
Why?
| | Pregnancy, Multiple | 1 | 2020 | 19 | 0.050 |
Why?
| | Breast Neoplasms | 2 | 2011 | 1929 | 0.050 |
Why?
| | Embryo Transfer | 1 | 2020 | 30 | 0.050 |
Why?
| | Leptin | 1 | 2002 | 236 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2022 | 476 | 0.050 |
Why?
| | Blastocyst | 1 | 2020 | 51 | 0.050 |
Why?
| | Fasting | 1 | 2002 | 273 | 0.050 |
Why?
| | Prostaglandins | 1 | 2000 | 85 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2019 | 137 | 0.050 |
Why?
| | Case-Control Studies | 4 | 2009 | 3269 | 0.050 |
Why?
| | Depression | 1 | 2008 | 1196 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2009 | 2106 | 0.040 |
Why?
| | Endotoxins | 1 | 2000 | 247 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2007 | 1233 | 0.040 |
Why?
| | Decompression, Surgical | 1 | 1999 | 104 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2018 | 76 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 1971 | 0.040 |
Why?
| | Denmark | 1 | 2017 | 35 | 0.040 |
Why?
| | Depressive Disorder, Major | 1 | 2001 | 327 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2022 | 786 | 0.040 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 15 | 0.040 |
Why?
| | Genetic Testing | 1 | 2020 | 383 | 0.040 |
Why?
| | Electromyography | 1 | 1999 | 336 | 0.040 |
Why?
| | Psychological Tests | 1 | 2018 | 135 | 0.040 |
Why?
| | Biostatistics | 1 | 2017 | 16 | 0.040 |
Why?
| | Viruses | 1 | 2018 | 91 | 0.040 |
Why?
| | Confidence Intervals | 2 | 2008 | 339 | 0.040 |
Why?
| | Signal-To-Noise Ratio | 1 | 2017 | 55 | 0.040 |
Why?
| | Milk | 1 | 2018 | 140 | 0.040 |
Why?
| | Incidence | 2 | 2017 | 2504 | 0.040 |
Why?
| | Depressive Disorder | 1 | 2000 | 384 | 0.040 |
Why?
| | Neoplasms | 1 | 2011 | 2139 | 0.040 |
Why?
| | Thyrotropin | 2 | 2007 | 106 | 0.040 |
Why?
| | Drug Combinations | 2 | 2011 | 303 | 0.040 |
Why?
| | Health Surveys | 2 | 2009 | 485 | 0.040 |
Why?
| | Lipopolysaccharides | 1 | 2000 | 903 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2018 | 267 | 0.040 |
Why?
| | Survival Analysis | 1 | 2019 | 1358 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 858 | 0.040 |
Why?
| | Dilatation, Pathologic | 1 | 2015 | 55 | 0.040 |
Why?
| | Escherichia coli | 1 | 2000 | 789 | 0.040 |
Why?
| | Gastrointestinal Diseases | 1 | 2017 | 204 | 0.040 |
Why?
| | Fatty Liver | 1 | 2018 | 277 | 0.030 |
Why?
| | Drug Users | 1 | 2015 | 39 | 0.030 |
Why?
| | Systole | 1 | 2015 | 189 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1405 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2015 | 251 | 0.030 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 759 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 1194 | 0.030 |
Why?
| | Electric Countershock | 1 | 2015 | 139 | 0.030 |
Why?
| | Phospholipids | 1 | 2015 | 206 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 566 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 2875 | 0.030 |
Why?
| | Risk | 1 | 2017 | 926 | 0.030 |
Why?
| | Substance Abuse, Intravenous | 1 | 2015 | 113 | 0.030 |
Why?
| | Psychometrics | 1 | 2018 | 690 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2018 | 3799 | 0.030 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 5136 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2015 | 678 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2018 | 665 | 0.030 |
Why?
| | Estrogens | 1 | 2015 | 306 | 0.030 |
Why?
| | Death, Sudden, Cardiac | 1 | 2015 | 229 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2015 | 414 | 0.030 |
Why?
| | Feeding Behavior | 1 | 2018 | 556 | 0.030 |
Why?
| | Follicular Phase | 2 | 2004 | 45 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 896 | 0.030 |
Why?
| | Fatty Acids | 1 | 2015 | 417 | 0.030 |
Why?
| | Mothers | 1 | 2018 | 664 | 0.030 |
Why?
| | Neuropsychological Tests | 2 | 2008 | 1115 | 0.030 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2018 | 499 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1584 | 0.030 |
Why?
| | Prognosis | 1 | 1999 | 3549 | 0.030 |
Why?
| | Defibrillators, Implantable | 1 | 2015 | 408 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2017 | 724 | 0.020 |
Why?
| | Abbreviated Injury Scale | 1 | 2010 | 20 | 0.020 |
Why?
| | Nasal Polyps | 1 | 2010 | 50 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 5230 | 0.020 |
Why?
| | Heart Transplantation | 1 | 2015 | 745 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2010 | 132 | 0.020 |
Why?
| | Heart-Assist Devices | 1 | 2015 | 470 | 0.020 |
Why?
| | Life Expectancy | 1 | 2010 | 72 | 0.020 |
Why?
| | Amides | 1 | 2010 | 87 | 0.020 |
Why?
| | Glasgow Coma Scale | 1 | 2010 | 152 | 0.020 |
Why?
| | Income | 1 | 2010 | 174 | 0.020 |
Why?
| | Family Characteristics | 1 | 2010 | 149 | 0.020 |
Why?
| | Benzodioxoles | 1 | 2010 | 78 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 337 | 0.020 |
Why?
| | Obstetrics | 1 | 2011 | 162 | 0.020 |
Why?
| | Norgestrel | 1 | 1988 | 3 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 835 | 0.020 |
Why?
| | Medroxyprogesterone | 1 | 1988 | 10 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 999 | 0.020 |
Why?
| | Administration, Intravaginal | 1 | 1988 | 38 | 0.020 |
Why?
| | Medroxyprogesterone Acetate | 1 | 1988 | 31 | 0.020 |
Why?
| | Poverty Areas | 1 | 2008 | 33 | 0.020 |
Why?
| | Thyroid Function Tests | 1 | 2008 | 13 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 389 | 0.020 |
Why?
| | Sheep | 2 | 2002 | 748 | 0.020 |
Why?
| | Receptors, Dopamine | 1 | 2008 | 21 | 0.020 |
Why?
| | Parity | 1 | 1988 | 103 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 282 | 0.020 |
Why?
| | Intelligence Tests | 1 | 2008 | 75 | 0.020 |
Why?
| | Employment | 1 | 2010 | 162 | 0.020 |
Why?
| | Smallpox | 1 | 2007 | 7 | 0.020 |
Why?
| | Galvanic Skin Response | 1 | 2007 | 23 | 0.020 |
Why?
| | Diphtheria | 1 | 2007 | 20 | 0.020 |
Why?
| | Gynecology | 1 | 2011 | 187 | 0.020 |
Why?
| | Personal Satisfaction | 1 | 2010 | 183 | 0.020 |
Why?
| | Tetanus | 1 | 2007 | 26 | 0.020 |
Why?
| | Cause of Death | 1 | 2010 | 399 | 0.020 |
Why?
| | Commerce | 1 | 2008 | 67 | 0.020 |
Why?
| | Virus Shedding | 1 | 2007 | 50 | 0.020 |
Why?
| | Contraindications | 1 | 2007 | 93 | 0.020 |
Why?
| | Half-Life | 1 | 2007 | 159 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2007 | 138 | 0.020 |
Why?
| | Educational Status | 1 | 2010 | 418 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 456 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2007 | 139 | 0.020 |
Why?
| | Plasma Cells | 1 | 2007 | 66 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2011 | 4842 | 0.020 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2007 | 48 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2007 | 48 | 0.020 |
Why?
| | Apolipoproteins E | 1 | 2007 | 87 | 0.020 |
Why?
| | Photic Stimulation | 1 | 2007 | 214 | 0.020 |
Why?
| | Thyroid Hormones | 1 | 2007 | 65 | 0.020 |
Why?
| | Thyroid Gland | 1 | 2007 | 85 | 0.020 |
Why?
| | Family Practice | 1 | 2011 | 479 | 0.020 |
Why?
| | Research | 1 | 2010 | 445 | 0.020 |
Why?
| | Age of Onset | 1 | 2008 | 470 | 0.020 |
Why?
| | Neural Inhibition | 1 | 2007 | 171 | 0.020 |
Why?
| | Safety | 1 | 2008 | 314 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 2007 | 113 | 0.020 |
Why?
| | Motor Skills | 1 | 2007 | 95 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2010 | 617 | 0.020 |
Why?
| | Mental Recall | 1 | 2007 | 202 | 0.020 |
Why?
| | Dopamine Agents | 1 | 2005 | 12 | 0.020 |
Why?
| | Inpatients | 1 | 2009 | 359 | 0.020 |
Why?
| | Virus Diseases | 1 | 2007 | 197 | 0.020 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2008 | 577 | 0.020 |
Why?
| | Vestibular Diseases | 1 | 2005 | 22 | 0.020 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2007 | 359 | 0.020 |
Why?
| | Presynaptic Terminals | 1 | 2005 | 56 | 0.020 |
Why?
| | Dizziness | 1 | 2005 | 77 | 0.020 |
Why?
| | Self Efficacy | 1 | 2008 | 354 | 0.020 |
Why?
| | Down-Regulation | 1 | 2007 | 648 | 0.020 |
Why?
| | Gait Disorders, Neurologic | 1 | 2005 | 44 | 0.020 |
Why?
| | Length of Stay | 1 | 2009 | 1046 | 0.020 |
Why?
| | Comorbidity | 1 | 2010 | 1650 | 0.020 |
Why?
| | Memory, Short-Term | 1 | 2007 | 263 | 0.020 |
Why?
| | Menarche | 1 | 2004 | 34 | 0.020 |
Why?
| | Diet Records | 1 | 2004 | 82 | 0.020 |
Why?
| | Research Design | 1 | 2010 | 968 | 0.020 |
Why?
| | Chronic Disease | 1 | 2010 | 1674 | 0.020 |
Why?
| | Overweight | 1 | 2008 | 495 | 0.020 |
Why?
| | Caregivers | 1 | 2010 | 684 | 0.010 |
Why?
| | Accidental Falls | 1 | 2005 | 164 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1209 | 0.010 |
Why?
| | Skin | 1 | 2007 | 699 | 0.010 |
Why?
| | Serotonin | 1 | 2005 | 379 | 0.010 |
Why?
| | Follicular Fluid | 1 | 2002 | 8 | 0.010 |
Why?
| | Dopamine | 1 | 2005 | 292 | 0.010 |
Why?
| | Neuraminidase | 1 | 2002 | 27 | 0.010 |
Why?
| | Adrenal Cortex | 1 | 2002 | 35 | 0.010 |
Why?
| | Contraceptives, Oral | 1 | 2002 | 28 | 0.010 |
Why?
| | Heart Failure | 1 | 2015 | 2029 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 2002 | 48 | 0.010 |
Why?
| | Dipeptides | 1 | 2002 | 51 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2002 | 211 | 0.010 |
Why?
| | Stress, Psychological | 1 | 2011 | 1149 | 0.010 |
Why?
| | Thinness | 1 | 2002 | 94 | 0.010 |
Why?
| | Postprandial Period | 1 | 2002 | 110 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2004 | 650 | 0.010 |
Why?
| | Pituitary Gland | 1 | 2002 | 169 | 0.010 |
Why?
| | Periodicity | 1 | 2000 | 62 | 0.010 |
Why?
| | Luteal Phase | 1 | 2000 | 46 | 0.010 |
Why?
| | HIV Infections | 1 | 2015 | 2512 | 0.010 |
Why?
| | Area Under Curve | 1 | 2001 | 314 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2002 | 344 | 0.010 |
Why?
| | Prostaglandin Antagonists | 1 | 2000 | 2 | 0.010 |
Why?
| | Depression, Chemical | 1 | 2000 | 28 | 0.010 |
Why?
| | Flurbiprofen | 1 | 2000 | 4 | 0.010 |
Why?
| | Energy Intake | 1 | 2004 | 516 | 0.010 |
Why?
| | Pain Measurement | 1 | 2002 | 527 | 0.010 |
Why?
| | Vaccination | 1 | 2007 | 1143 | 0.010 |
Why?
| | Fever | 1 | 2000 | 300 | 0.010 |
Why?
| | Hypertension | 1 | 2007 | 1202 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2206 | 0.010 |
Why?
| | Sleep | 1 | 2002 | 772 | 0.010 |
Why?
| | Mice | 1 | 2007 | 15537 | 0.010 |
Why?
|
|
Carlson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|